Ozurdex is an intravitreal implant containing 700 micograms of dexamethasone. It is indicated for the treatment of macular oedema following either branch retinal vein occlusion or central retinal vein occlusion. Treatment must be administered by an ophthalmologist.
Researchers tested Ozurdex in two double-blind, randomised trials in a total of 1267 patients. At 90 days after a single injection, the proportion of patients who had responded was significantly greater in the Ozurdex group than in the sham treatment group (21.8% vs 13.1%, p<0.001). Response was defined as an improvement of 15 letters or more in best corrected visual acuity.
Corticosteroids such as dexamethasone suppress the production of vascular endothelial growth factor, a cytokine that is involved in the development of macular oedema.
Further information: Allergan